Oxford Immunotec Global PLC (NASDAQ:OXFD) CEO Peter Wrighton-Smith sold 10,000 shares of the firm’s stock in a transaction on Thursday, January 10th. The shares were sold at an average price of $14.91, for a total value of $149,100.00. Following the sale, the chief executive officer now directly owns 423,469 shares of the company’s stock, valued at approximately $6,313,922.79. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Shares of Oxford Immunotec Global stock opened at $14.90 on Monday. Oxford Immunotec Global PLC has a 1 year low of $10.00 and a 1 year high of $19.19. The firm has a market cap of $387.25 million, a price-to-earnings ratio of -10.96 and a beta of 0.11.
Oxford Immunotec Global (NASDAQ:OXFD) last announced its quarterly earnings results on Friday, November 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.14). Oxford Immunotec Global had a negative net margin of 12.51% and a negative return on equity of 41.15%. The business had revenue of $16.10 million for the quarter, compared to analyst estimates of $33.60 million. During the same period in the prior year, the business earned ($0.70) EPS. The company’s revenue for the quarter was up 7.3% compared to the same quarter last year. Equities research analysts expect that Oxford Immunotec Global PLC will post -1.09 earnings per share for the current fiscal year.
Several equities research analysts have issued reports on the company. Zacks Investment Research raised Oxford Immunotec Global from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a report on Thursday. BidaskClub raised Oxford Immunotec Global from a “sell” rating to a “hold” rating in a report on Thursday. ValuEngine downgraded Oxford Immunotec Global from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 1st. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating on shares of Oxford Immunotec Global in a report on Sunday, November 11th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $16.67.
A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc lifted its holdings in Oxford Immunotec Global by 2.0% during the 3rd quarter. Vanguard Group Inc now owns 95,647 shares of the company’s stock valued at $1,552,000 after purchasing an additional 1,839 shares during the last quarter. Wells Fargo & Company MN increased its position in Oxford Immunotec Global by 11.2% during the 3rd quarter. Wells Fargo & Company MN now owns 45,820 shares of the company’s stock worth $744,000 after buying an additional 4,605 shares during the period. Citadel Advisors LLC increased its position in Oxford Immunotec Global by 6.2% during the 3rd quarter. Citadel Advisors LLC now owns 84,689 shares of the company’s stock worth $1,375,000 after buying an additional 4,911 shares during the period. Northern Trust Corp increased its position in Oxford Immunotec Global by 3.1% during the 2nd quarter. Northern Trust Corp now owns 265,487 shares of the company’s stock worth $3,423,000 after buying an additional 7,862 shares during the period. Finally, Renaissance Technologies LLC increased its position in Oxford Immunotec Global by 84.7% during the 2nd quarter. Renaissance Technologies LLC now owns 21,058 shares of the company’s stock worth $271,000 after buying an additional 9,658 shares during the period. 90.94% of the stock is owned by institutional investors and hedge funds.
About Oxford Immunotec Global
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.
Recommended Story: Earnings Reports
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.